Intervention

dutasteride

ClinicalTrials.gov intervention label

Clinical trials8

Recruiting0

Common conditions3

Lead sponsors shown7

Clinical trials

8 shown

Dutasteride in Treating Patients With Prostate CancerNCT01193855 · 2010-06-01

Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate CancerNCT00953576 · 2009-09-29

ARI103094-Follow-Up Study for REDUCE Study SubjectsNCT00883909 · 2009-04-09

Prostate Cancer Study In Men Who Have Failed First-Line Androgen Deprivation TherapyNCT00470834 · 2007-05-01

Prevention of Prostate Cancer With Dutasteride in Case of High Grade PIN NeoplasiaNCT00780754 · 2007-04-01

Dutasteride Followed By Ultrasound-Guided Biopsy in Finding Prostate CancerNCT00398281 · 2006-11-01

MRI and Magnetic Resonance Spectroscopy Imaging in Patients Receiving Dutasteride for Benign Prostatic Hypertrophy and Low-Risk Prostate CancerNCT00706966 · 2005-06-01

Dutasteride in Treating Patients With Recurrent Prostate Cancer That Did Not Respond to Androgen-Deprivation TherapyNCT00403000 · 2004-12-01

Common conditions

Prostate Cancer6 Neoplasms, Prostate2 Nonmalignant Neoplasm1

Leading sponsors

GlaxoSmithKline2 Dana-Farber Cancer Institute1 Kaunas University of Medicine1 Roswell Park Cancer Institute1 Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University1 University College London Hospitals1 University of California, San Francisco1

Trial status mix

COMPLETED6

TERMINATED1

UNKNOWN1

Phase mix

PHASE23

PHASE32

NA1

PHASE11

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.